FDA danuglipron coverage for business development, investment, and market access teams
Latest on danuglipron
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
Pfizer said its oral GLP-1 danuglipron met the primary endpoint in a Phase 2b obesity trial, showing a statistically significant change in body weight from baseline. The result strengthens the case for Pfizer's oral GLP-1 strategy and sets up investor and BD scrutiny around Phase 3 design, safety, and differentiation.
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.